title: Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species.
abstract: Since the separation of Pseudallescheria boydii and P. apiosperma in 2010, limited data on species-specific susceptibility patterns of these and other species of Pseudallescheria and its anamorph Scedosporium have been reported. This study presents the antifungal susceptibility patterns of members affiliated with both entities. Clinical and environmental isolates (n = 332) from a wide range of sources and origins were identified down to species level and tested according to CLSI M38-A2 against eight antifungal compounds. Whereas P. apiosperma (geometric mean MIC/minimal effective concentration [MEC] values of 0.9, 2.4, 7.4, 16.2, 0.2, 0.8, 1.5, and 6.8 μg/ml for voriconazole, posaconazole, isavuconazole, itraconazole, micafungin, anidulafungin, caspofungin, and amphotericin B, respectively) and P. boydii (geometric mean MIC/MEC values of 0.7, 1.3, 5.7, 13.8, 0.5, 1.4, 2.3, and 11.8 μg/ml for voriconazole, posaconazole, isavuconazole, itraconazole, micafungin, anidulafungin, caspofungin, and amphotericin B, respectively) had similar susceptibility patterns, those for S. aurantiacum, S. prolificans, and S. dehoogii were different from each other. Voriconazole was the only drug with significant activity against S. aurantiacum isolates. The MIC distributions of all drugs except voriconazole did not show a normal distribution and often showed two subpopulations, making a species-based prediction of antifungal susceptibility difficult. Therefore, antifungal susceptibility testing of all clinical isolates remains essential for targeted antifungal therapy. Voriconazole was the only compound with low MIC values (MIC(90) of ≤ 2 μg/ml) for P. apiosperma and P. boydii. Micafungin and posaconazole showed moderate activity against the majority of Scedosporium strains.
authors.affiliation: Federal Institute for Drugs and Medical Devices Biosafety Laboratory, Bonn, Germany.
authors.forename: Michaela
authors.initials: M
authors.lastname: Lackner
authors.forename: G Sybren
authors.initials: GS
authors.lastname: de Hoog
authors.forename: Paul E
authors.initials: PE
authors.lastname: Verweij
authors.forename: Mohammad J
authors.initials: MJ
authors.lastname: Najafzadeh
authors.forename: Ilse
authors.initials: I
authors.lastname: Curfs-Breuker
authors.forename: Corné H
authors.initials: CH
authors.lastname: Klaassen
authors.forename: Jacques F
authors.initials: JF
authors.lastname: Meis
mesh_terms: D054458:Amplified Fragment Length Polymorphism Analysis; D000935:Antifungal Agents / Q000494:pharmacology*; D015373:Bacterial Typing Techniques; D004305:Dose-Response Relationship, Drug; D025141:Drug Resistance, Fungal; D054714:Echinocandins / Q000494:pharmacology*; D006801:Humans; D055666:Lipopeptides / Q000494:pharmacology*; D000077551:Micafungin; D008826:Microbial Sensitivity Tests; D011541:Pseudallescheria / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D011743:Pyrimidines / Q000494:pharmacology*; D021681:Scedosporium / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D013045:Species Specificity; D014230:Triazoles / Q000494:pharmacology*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D011743:Pyrimidines; D014230:Triazoles; C101425:posaconazole; D065819:Voriconazole; D000077551:Micafungin